Cardiovascular risk estimation in 2012: Lessons learned and applicability to the HIV population

Journal of Infectious Diseases

Volumn 205, Issue SUPPL. 3, 2012, Pages

  D'Agostino, Ralph B ^a,b  

^a Boston University   (United States)

^b Framingham Study   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; INDINAVIR; LOPINAVIR PLUS RITONAVIR;

ACUTE HEART INFARCTION; AGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; DIABETES MELLITUS; DYSLIPIDEMIA; FRAMINGHAM RISK SCORE; HEART FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIVIDUALIZATION; ISCHEMIC HEART DISEASE; MEDICAL RESEARCH; PERIPHERAL VASCULAR DISEASE; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; STROKE; SYSTOLIC BLOOD PRESSURE; VALIDITY;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; HIV INFECTIONS; HUMANS; RISK FACTORS; TIME FACTORS; UNITED STATES; WORLD HEALTH;

EID: 84861076398     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis196     Document Type: Review

References (39)

1. Dawber TR. The Framingham study: the epidemiology of atherosclerotic disease. Cambridge, MA: Harvard University Press, 1980.
2. D'Agostino Sr RB, Kannel WB. Epidemiological background and design: the Framingham Study. In: Proceedings of the American Statistical Association sesquicentennial invited paper sessions. Alexandria, VA: American Statistical Association, 1989.
3. Dawber TR, Meadors GF, Moore FE Jr. Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health Nations Health 1951; 41:279.
4. Dawber TR, Kannel WB, Lyell LP. An approach to longitudinal studies in a community: the Framingham Study. Ann N Y Acad Sci 1963; 107:539-56.
5. Dawber TR, Moore FE. Longitudinal study of heart disease in Framingham,Massachusetts: an interim report; research in public health. In: Papers presented at the 1951 Annual Conference of the Milbank Memorial Fund. New York, NY: Milbank Memorial Fund, 1952; 241-7.
6. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families. The Framingham Offspring Study. Am J Epidemiol 1979; 110:281-90. (Pubitemid 10204328)
7. Splansky GL, Corey D, Yang Q, et al. The Third Generation Cohort of the National Heart, Lung, and Blood Institute's Framingham Heart Study: design, recruitment, and initial examination. Am J Epidemiol 2007; 165:1328-35. (Pubitemid 47234329)
8. Kannel WB. Multivariate evaluation of candidates for cardiovascular disease. In: Rosendorff C, ed. Essential cardiology principles and practice. 2nd ed. Totowa, NJ: Humana Press, 2006: 3.
9. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837-47. (Pubitemid 28213628)
10. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991; 83:356-62.
11. D'Agostino R, Grundy S, Sullivan L, Wilson P. Validation of the Framingham coronary heart disease prediction scores: Results of a multiple ethnic group investigation. JAMA 2001; 286:180-7. (Pubitemid 32640849)
12. Wolf PA, D'Agostino RB, Belanger AJ, KannelWB. Probability of stroke: a risk profile from the Framingham Study. Stroke 1991; 22:312-18.
13. D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117:743-53. (Pubitemid 351640675)
14. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-97.
15. Grundy SM. Primary prevention of coronary heart disease: integrating risk assessment with intervention. Circulation 1999; 100:988-98. (Pubitemid 29407181)
16. Sullivan LM, Massaro JM, D'Agostino RB Sr. Presentation of multivariate data for clinical use: the Framingham Study risk score functions. Stat Med 2004; 23:1631-0.
17. Kannel WB, McGee D, Gordon T. A general cardiovascular risk profile: the Framingham Study. Am J Cardiol 1976; 38:46-51.
18. Abbott RD, McGee D. National Heart L, Blood I, US Department of Commerce. National Technical Information Service N. The Framingham Study: an epidemiological investigation of cardiovascular disease: Section 37: the probability of developing certain cardiovascular diseases in eight years specified values of some characteristics. Springfield, VA: National Technical Information Service, 1987.
19. D'Agostino RB, Nam B-H. Evaluation of the performance of survival analysis models: discrimination and calibration measures. In: Balakrishnan N, Rao CR, eds. Amsterdam: Handbook of statistics. Vol 23. Elsevier, 2003; 1-25.
20. Pencina MJ, D'Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 2004; 23:2109-23. (Pubitemid 38968032)
21. Marrugat J, D'Agostino R, Sullivan L, et al. An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas. J Epidemiol Community Health 2003; 57:634-8. (Pubitemid 36930293)
22. Liu J, Hong Y, D'Agostino RB Sr, et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA 2004; 291: 2591-9. (Pubitemid 38702777)
23. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15:361-87. (Pubitemid 26072233)
24. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991; 121:293-8.
25. Risk score profiles. Framingham Heart Study Web site. Available at: http://www.framinghamheartstudy.org/risk/index.html. Accessed 30 November 2011.
26. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92:2506-12. (Pubitemid 47037350)
27. Schambelan M, Wilson PW, Yarasheski KE, et al. Development of appropriate coronary heart disease risk prediction models in HIV-infected patients. Circulation 2008; 118:e48-53.
28. Grinspoon SK, Grunfeld C, Kotler DP, et al. State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation 2008; 118:198-210.
29. Bastuji-Garin S, Deverly A, Moyse D, et al. The Framingham prediction rule is not valid in a European population of treated hypertensive patients. J Hypertens 2002; 20:1973-80. (Pubitemid 35305494)
30. Brindle PM, McConnachie A, Upton MN, Hart CL, Davey Smith G, Watt GC. The accuracy of the Framingham risk-score in different socioeconomic groups: a prospective study. Br J Gen Pract 2005; 55:838-45. (Pubitemid 41683997)
31. Hadigan C, Meigs J, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in Adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001; 32: 130-9. doi:10.1086/317541. (Pubitemid 32150958)
32. Hadigan C, Meigs JB, Wilson PW, et al. Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution. Clin Infect Dis 2003; 36:909-16. (Pubitemid 36403525)
33. Knobel H, Jerico C, Montero M, et al. Global cardiovascular risk in patients with HIV infection: concordance and differences in estimates according to three risk equations (Framingham, SCORE, and PROCAM). AIDS Patient Care STDS 2007; 21:452-7. (Pubitemid 47224837)
34. Moreira Guimaraes MM, Bartolomeu Greco D, Ingles Garces AH, et al. Coronary heart disease risk assessment in HIV-infected patients: a comparison of Framingham, PROCAM and SCORE risk assessment functions. Int J Clin Pract 2010; 64:739-45.
35. Barros ZM, de Alencar Ximenes RA, Miranda-Filho DB, et al. Comparison between the Framingham and prospective cardiovascular of Munster scores for risk assessment of coronary heart disease in human immunodeficiency virus-positive patients in Pernambuco, Brazil. Metab Syndr Relat Disord 2010; 8:489-97.
36. Edwards-Jackson N, Kerr S, Tieu H, et al. Cardiovascular risk assessment in persons with HIV infection in the developing world: comparing three risk equations in a cohort of HIV-infected Thais. HIV Med 2011; 12:510-5.
37. Law MG, Friis-Moller N, El-Sadr WM, et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D: A:D Study. HIV Med 2006; 7:218-30.
38. May M, Sterne JA, Shipley M, et al. A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men. Int J Epidemiol 2007; 36:1309-18. (Pubitemid 350239000)
39. Friis-Moller N, Thiebaut R, Reiss P, et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil 2010; 17:491-501.